

CD52 Protein, Cynomolgus, Recombinant (hFc)

General Information

Synonyms:	CD52 molecule
Protein Construction:	A DNA sequence encoding the cynomolgus CD52 (NP_001253116.1) (Met1-Ser35) was expressed with the Fc region of human IgG1 at the C-terminus. Predicted N terminal: Ser 25
Species:	Cynomolgus
Expression Host:	HEK293 Cells
Accession:	NP_001253116.1
Molecular Weight:	27.82 kDa (predicted)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95 % as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:
In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

CD52 / CDW52 is a small glycosylphosphatidylinositol (GPI) anchored glycoprotein. It has a mature peptide comprising only 12 amino acids and is abundantly expressed on human lymphocytes. From the clinical point of view this protein is an important target for therapeutic interventions aimed at leukocyte depletion in hematological malignancies and post-transplant immunosuppression. CD52 / CDW52 may play a role in carrying and orienting carbohydrate. It is an unusually good target for complement-mediated cell lysis. Cancer

ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

Reference

Piccaluga PP,et al.(2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica. 92(4): 566-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481